Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

被引:26
|
作者
Privitera, Michael [1 ]
Bhathal, Hari [2 ]
Wong, Matthew [3 ]
Cross, J. Helen [4 ]
Wirrell, Elaine [5 ]
Marsh, Eric D. [6 ]
Mazurkiewicz-Beldzinska, Maria [7 ]
Villanueva, Vicente [8 ]
Checketts, Daniel [9 ]
Knappertz, Volker [10 ]
VanLandingham, Kevan [10 ]
机构
[1] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[2] Neuroctr Barcelona, Teknon Med Ctr, Barcelona, Spain
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] UCL, Great Ormond St Inst Child Hlth, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[5] Mayo Clin, Rochester, MN USA
[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[7] Med Univ Gdansk, Gdansk, Poland
[8] Univ & Polytech Hosp La Fe, Valencia, Spain
[9] GW Res Ltd, Cambridge, England
[10] Greenwich Biosci Inc, Carlsbad, CA USA
关键词
antiepileptic drug; antiseizure medication; childhood onset epilepsy; drop seizures; treatment‐ resistant epilepsy;
D O I
10.1111/epi.16878
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox-Gastaut syndrome. Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. Results Overall, 235 patients received CBD (CBD10 [GWPCARE3 only], n = 67; CBD20 [pooled GWPCARE3&4], n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6-48.0). Patients had previously discontinued a median (range) of six (0-28) antiepileptic drugs (AEDs) and were currently taking a median of three (0-5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in >= 50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients. Significance Treatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14-week period.
引用
收藏
页码:1130 / 1140
页数:11
相关论文
共 50 条
  • [1] Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials
    Mazurkiewicz-Beldzinska, Maria
    Privitera, Michael
    Marsh, Eric
    Villanueva, Vicente
    VanLandingham, Kevan
    Checketts, Daniel
    Knappertz, Volker
    NEUROLOGY, 2019, 92 (15)
  • [2] Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) Enrolled in Three Randomized Controlled Trials
    Marsh, E.
    Privitera, M.
    Mazurkiewicz-Beldzinska, M.
    Villanueva, V.
    Checketts, D.
    Knappertz, V
    ANNALS OF NEUROLOGY, 2019, 86 : S69 - S70
  • [3] Time To Onset Of Efficacy Of Cannabidiol (CBD) During Titration In Patients With Lennox-Gastaut Syndrome Or Dravet Syndrome Enrolled In Three Randomised Controlled Trials
    Mazurkiewicz-Beldzinska, M.
    Privitera, M.
    Marsh, E.
    Villanueva, V.
    VanLandingham, K.
    Checketts, D.
    Knappertz, V.
    EPILEPSIA, 2019, 60 : 64 - 64
  • [4] Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials
    Wirrell, E.
    Privitera, M.
    Bhathal, H.
    Wong, M.
    Cross, J.
    Sommerville, K.
    ANNALS OF NEUROLOGY, 2018, 84 : S341 - S341
  • [5] Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials
    Wirrell, Elaine C.
    Privitera, Michael
    Bhathal, Hari
    Wong, Matthew H.
    Cross, J. Helen
    Sommerville, Kenneth
    NEUROLOGY, 2018, 90
  • [6] Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox-Gastaut Syndrome
    Morrison, Gilmour
    Sardu, Maria Luisa
    Rasmussen, Christian Hove
    Sommerville, Kenneth
    Roberts, Claire
    Blakey, Graham E.
    NEUROLOGY, 2018, 90
  • [7] Cannabidiol Treatment Effect and Adverse Events in Patients with Lennox-Gastaut Syndrome: Pooled Results from Two Trials
    Gil-Nagel, A.
    Privitera, M.
    Bhathal, H.
    Wong, M. H.
    Cross, J. H.
    Wirrell, E. C.
    Sommerville, K.
    Roberts, C.
    EPILEPSIA, 2018, 59 : S13 - S14
  • [8] Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
    Devinsky, Orrin
    Patel, Anup D.
    Cross, J. Helen
    Villanueva, Vicente
    Wirrell, Elaine C.
    Privitera, Michael
    Greenwood, Sam M.
    Roberts, Claire
    Checketts, Daniel
    VanLandingham, Kevan E.
    Zuberi, Sameer M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20): : 1888 - 1897
  • [9] Exposure-Response Analysis of Cannabidiol for the Treatment of Lennox-Gastaut Syndrome
    Morrison, G.
    Sardu, M. L.
    Rasmussen, C. H.
    Sommerville, K.
    Roberts, C.
    Blakey, G. E.
    EPILEPSIA, 2018, 59 : S11 - S12
  • [10] The efficacy and safety of fenfluramine in the treatment of Dravet syndrome and Lennox-Gastaut syndrome: evidence from randomized controlled trials
    Xu, Y.
    Chen, D.
    Liu, J.
    Chen, Y.
    Liu, L.
    EPILEPSIA, 2023, 64 : 518 - 519